InvestorsHub Logo
Followers 12
Posts 186
Boards Moderated 0
Alias Born 01/07/2014

Re: None

Wednesday, 11/12/2014 11:11:11 AM

Wednesday, November 12, 2014 11:11:11 AM

Post# of 9944
Phase 3 protocol posted on Clinicaltrials.gov

New CTD post has the link. http://clinicaltrials.gov/ct2/show/NCT02288897?term=provectus&recr=Open&rank=2

Why is the study limited to patients with no more than 20 lesions? Also confused by the reference to 25 lesions ("Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at Day 29 (Week 5) and/or Day 57 (Week 9) for treatment of any existing disease on the skin (not exceeding 25 Study Lesions) and thereafter at 28-day intervals until complete response, disease progression or study termination occurs.")
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PVCT News